Whereas GLP-1 forms the basis for many glucose-lowering and anti-obesity drugs such as liraglutide and semaglutide [2, 3], GIP-based therapeutics have lagged behind due to early concerns that GIP had only weak activity in the context of type 2 diabetes [4]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.